Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

FA-70, A Novel Selective and Irreversible Monoamine Oxidase-A Inhibitor: Effect on Monoamine Metabolism in Mouse Cerebral Cortex

José A. Morón, Virgili Pérez, Manel Pastó, José Miguel Lizcano and Mercedes Unzeta
Journal of Pharmacology and Experimental Therapeutics February 2000, 292 (2) 788-794;
José A. Morón
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virgili Pérez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manel Pastó
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Miguel Lizcano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mercedes Unzeta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A series of indolealkylamine derivatives has been previously designed and evaluated with the aim of finding the most potent and selective novel monoamine oxidase (MAO) inhibitors to be used in the therapy of neurological and affective disorders. Among them, FA70, a 5-hydroxy-indolealkylamine derivative, has been characterized in vitro as a potent, irreversible, and mechanism-based inhibitor of the MAO-A isoform. The comparison with clorgyline, analyzed under the same experimental conditions, confirmed FA70 as the most potent MAO-A inhibitor. The ex vivo effect of FA70 on MAO activity in mouse cerebral cortex was similar to that observed in vitro, showing more efficacy than in peripheral tissues. The ex vivo effect of FA70 on amine metabolism also was evaluated after acute and chronic treatment, and the results showed that between both MAO isoforms, MAO-A is the only one responsible for monoamine metabolism in this region of the brain. The ex vivo effect of FA70 on dopamine content was correlated with the activation effect on tyrosine hydroxylase activity, the enzyme responsible for the regulation of the limiting step in catecholamine synthesis.

Footnotes

  • Send reprint requests to: Dr. Mercedes Unzeta, Departament Bioquimica i Biologia Molecular, Facultat de Medicina, Universitat Autónoma de Barcelona, Campus Universitari de Bellaterra, E-08193 Bellaterra, Barcelona, Spain. E-mail:Mercedes.Unzeta{at}uab.es

  • ↵1 This work was supported in part by Programa de Estimulo a la Transferencia de Resultados de Investigacion-Comision Interministerial de Ciencia y Technologia Grant ref-95-01333 OP, Secretaria General del Plan Nacional de I+D.

  • Abbreviations:
    MAO
    monoamine oxidase
    NA
    noradrenaline
    PEA
    phenylethylamine
    DA
    dopamine
    5-HT
    5-hydroxytryptamine (serotonin)
    DOPAC
    3,4-dihydroxyphenylacetic acid
    HVA
    homovanillic acid
    3-MT
    3-methoxytyramine
    5-HIAA
    5-hydroxyindole acetic acid
    • Received February 11, 1999.
    • Accepted October 25, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 292 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 292, Issue 2
1 Feb 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
FA-70, A Novel Selective and Irreversible Monoamine Oxidase-A Inhibitor: Effect on Monoamine Metabolism in Mouse Cerebral Cortex
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

FA-70, A Novel Selective and Irreversible Monoamine Oxidase-A Inhibitor: Effect on Monoamine Metabolism in Mouse Cerebral Cortex

José A. Morón, Virgili Pérez, Manel Pastó, José Miguel Lizcano and Mercedes Unzeta
Journal of Pharmacology and Experimental Therapeutics February 1, 2000, 292 (2) 788-794;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

FA-70, A Novel Selective and Irreversible Monoamine Oxidase-A Inhibitor: Effect on Monoamine Metabolism in Mouse Cerebral Cortex

José A. Morón, Virgili Pérez, Manel Pastó, José Miguel Lizcano and Mercedes Unzeta
Journal of Pharmacology and Experimental Therapeutics February 1, 2000, 292 (2) 788-794;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Macrophages Mediate Neuropathic Pain in Type 2 Diabetes
  • Effect of Acetyl-l-Carnitine on Functional Recovery
  • Mechanism-Based Pharmacokinetic-Pharmacodynamic Model Describing Dextroamphetamine Exposure and Striatal Dopamine Response in Rats and Non-Human Primates following a Single Intravenous Dose of Dextroamphetamine
Show more Neuropharmacology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics